Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity

NCT ID: NCT00858624

Last Updated: 2013-06-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2009-07-31

Brief Summary

A cough lasting more than 2 months is known as a chronic cough, affecting 12-23% of the adult non-smoking population. Chronic cough has many associated complications including incontinence, muscular chest pains, blackouts and depression. Current treatment is often ineffective in these patients. To develop new medications the investigators need to understand more about the mechanisms that can lead to excessive coughing.

This study plans to compare a group of 12 healthy volunteers and 12 patients with a chronic cough. The investigators hypothesise that that chronic cough patients have a more sensitive cough reflex as a result central nervous system hyper-excitability (central sensitisation). The investigators will measure cough reflex sensitivity before and after administration of ketamine, a medication that blocks an important receptor in the central nervous system.

Conditions

Chronic Cough

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: DOUBLE

Study Groups

Chronic Cough Patients

Group Type: ACTIVE_COMPARATOR

ketamine

Intervention Type: DRUG

Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.

Healthy Volunteers

Group Type: ACTIVE_COMPARATOR

ketamine

Intervention Type: DRUG

Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.

Interventions

ketamine

Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Healthy Volunteers:

• Over 18 years old
• Measurable cough reflex sensitivity
• No current or past history of chronic cough or chronic respiratory disease.
• No symptoms of gastro-oesophageal reflux disease, asthma or post-nasal drip.

Chronic Cough Patients

• Over 18 years old
• Chronic persistent cough (> 8 weeks) despite investigation and/or treatment trials for cough variant asthma/post nasal drip and gastro-oesophageal reflux disease.
• Normal CXR
• Normal lung function
• Measurable cough reflex sensitivity

Exclusion Criteria

• Recent Upper Respiratory Tract Infection (4 weeks)
• Pregnancy/breast feeding
• Current smokers or ex-smokers with < 6 months abstinence or cumulative history of > 10 packyears
• Diabetes Mellitus
• Opiate or ACE Inhibitor use.
• Any centrally acting medication which has the potential to alter cough reflex sensitivity.
• Significant and ongoing chronic respiratory, cardiovascular (in particular hypertension), gastro-intestinal, haematological (porphyria), neurological or psychiatric illness.
• Drug or alcohol abuse
• History of allergy or reaction to ketamine of other NMDA receptor antagonists.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Jacky Smith

OTHER

Sponsor Role: lead

Responsible Party

Jacky Smith

Reader

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

University of Manchester, Education and Research Centre, Wythenshawe Hospital

Manchester, Manchester, United Kingdom

Countries

United Kingdom

Other Identifiers

07/H1004/142

Identifier Type: -

Identifier Source: org_study_id